-
2022-502046-28-00
5
2023-12-22
HER2-Positive, PIK3CA Mutated, Locally Advanced or Metastatic Breast C
-
2022-502703-30-00
6
2023-06-28
neuroendocrine tumours
-
2022-500311-39-00
6
2022-09-08
Patients with Crohn's disease undergoing surgery and having at least o
-
2025-521067-13-00
5
2026-04-24
Atherosclerotic Cardiovascular Disease (ASCVD)
-
2024-511016-25-00
4
2025-01-15
Chronic hepatitis B infection
-
2023-509190-23-00
5
2024-09-03
Atherosclerotic Cardiovascular Disease
Elevated lp(a)
-
2023-508896-35-00
6
2024-07-12
Infertile women with at least one patent tube at Hysterosalpingo-foam
-
2023-506668-15-00
5
2024-06-17
Relapsed or Refractory Multiple Myeloma (RRMM)
-
2023-508630-34-00
5
2024-05-28
Overweight
-
2023-506906-38-00
5
2024-05-23
Follicular Lymphoma
-
2023-505928-59-00
5
2024-04-15
Triple Negative or Hormone Receptor low/HER2-negative Breast Cancer
-
2023-503827-25-01
5
2024-02-16
Non-Small Cell Lung Cancer (NSCLC)
-
2022-502593-17-00
5
2023-09-19
Locally advanced or metastatic hormone receptor (HR)-positive, human e
-
2022-501024-20-00
5
2023-07-25
ER+/HER2- Early Breast Cancer
-
2023-503444-13-00
5
2023-03-29
Relapsed/refractory multiple myeloma
-
2023-504195-14-00
5
2022-08-31
PD-L1-negative metastatic triple-negative breast cancer or PD-L1-posit
-
2023-504996-26-00
5
2022-07-21
Metastatic Castration Resistant Prostate Cancer (mCRPC)
-
2024-516914-39-00
5
2022-04-27
Metastatic or unresectable melanoma
-
2023-506771-10-00
5
2022-03-11
Breast Neoplasm, Neoplasm Metastasis
-
2024-510735-21-00
5
2021-11-26
Atherosclerotic cardiovascular disease (ASCVD)
-
2023-506926-35-00
5
2021-09-24
Atherosclerotic cardiovascular disease, chronic kidney disease and sys
-
2023-504997-39-00
5
2021-06-14
Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2
-
2023-507961-24-00
5
2021-04-19
High-Risk HER2-Positive Breast Cancer
-
2023-509120-17-00
5
2021-04-12
Myelofibrosis